Editas Medicine
Main focus: Gene editing for the treatment of genetic diseases and cancer
Company stage: Clinical
Diseases: Sickle Cell Disease (SCD), Leber Congenital Amaurosis 10 (LCA10), Usher Syndrome 2a (USH2A), Autosomal Dominant Retinitis Pigmentosa 4 (RP4) , β-Thalassemia.
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:EDIT)
Location: Cambridge, MA, USA
Website: https://www.editasmedicine.com/
Pipeline: https://www.editasmedicine.com/gene-editing-pipeline/
Partners: Bluerock Therapeutics, Gamida Cell, Bristol Myers Squibb, Askbio, Sandhill Therapeutics
Editas Medicine is a US-based public gene therapy company. Editas has advanced two drugs into early stage clinical trials focusing on ocular disease and sickle cell disease, and the company also has several ongoing pre-clinical programmes. All of the company's trials are focused on two gene-editing technologies, CRISPR-Cas9 and CRISPR-Cas12a.